Enhance your lab operations and funding strategies with actionable advice on equipment leasing, financing, procurement, and life sciences industry trends.

Expedition Therapeutics secures $165M Series A to advance EXPD-101, a first-in-class oral DPP-1 inhibitor for COPD—Excedr covers this major biotech funding round.
October 2025

Lumen Bioscience pioneers affordable oral biologic drugs using engineered spirulina—Excedr covers this major biotech funding round.
October 2025






Ansa Biotechnologies secures $54M+ Series B to advance enzymatic DNA synthesis—Excedr covers this major biotech funding round.
October 2025

Cartography Biosciences secures $67M Series B to advance precision cancer immunotherapies—Excedr covers this major biotech funding round.
October 2025
